NEW YORK, NY / ACCESS Newswire / July 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Summit Therapeutics Inc. ("Summit" or "the Company") (NASDAQ:SMMT). Investors who purchased Summit securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SMMT.

Investigation Details

On May 30, 2025, Summit announced the topline results from its Phase III "Harmoni" clinical trial. The Company's ivonescimab drug did not demonstrate a significant difference in overall survivability during the trial. Following this news, Summit stock dropped by 30.5% on the same day.

What's Next?

If you are aware of any facts relating to this investigation or purchased Summit securities, you can assist this investigation by visiting the firm's site: bgandg.com/SMMT. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller

332-239-2660 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View the original press release on ACCESS Newswire